{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:23:11Z","timestamp":1790479391367,"version":"4.1.0"},"reference-count":114,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,5,5]],"date-time":"2019-05-05T00:00:00Z","timestamp":1557014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004515","name":"Universiti Kebangsaan Malaysia","doi-asserted-by":"publisher","award":["FF-2018-404"],"award-info":[{"award-number":["FF-2018-404"]}],"id":[{"id":"10.13039\/501100004515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004515","name":"Universiti Kebangsaan Malaysia","doi-asserted-by":"publisher","award":["GUP-2017-012"],"award-info":[{"award-number":["GUP-2017-012"]}],"id":[{"id":"10.13039\/501100004515","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>The number of patients with gastroesophageal problems taking proton pump inhibitors (PPIs) is increasing. Several studies suggested a possible association between PPIs and fracture risk, especially hip fractures, but the relationship remains contentious. This review aimed to investigate the longitudinal studies published in the last five years on the relationship between PPIs and fracture risk. The mechanism underlying this relationship was also explored. Overall, PPIs were positively associated with elevated fracture risk in multiple studies (n = 14), although some studies reported no significant relationship (n = 4). Increased gastrin production and hypochlorhydria are the two main mechanisms that affect bone remodeling, mineral absorption, and muscle strength, contributing to increased fracture risk among PPI users. As a conclusion, there is a potential relationship between PPIs and fracture risks. Therefore, patients on long-term PPI treatment should pay attention to bone health status and consider prophylaxis to decrease fracture risk.<\/jats:p>","DOI":"10.3390\/ijerph16091571","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T08:19:59Z","timestamp":1557389999000},"page":"1571","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-6936","authenticated-orcid":false,"given":"Benjamin Ka Seng","family":"Thong","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Universiti Kebangsaan Malaysia Medical Centre, Cheras 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-438X","authenticated-orcid":false,"given":"Soelaiman","family":"Ima-Nirwana","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Universiti Kebangsaan Malaysia Medical Centre, Cheras 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-1552","authenticated-orcid":false,"given":"Kok-Yong","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Universiti Kebangsaan Malaysia Medical Centre, Cheras 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_2","unstructured":"Howden, C. (2004). Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1136\/bmj.38356.641134.8F","article-title":"Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding","volume":"330","author":"Leontiadis","year":"2005","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/j.1365-2036.2005.02444.x","article-title":"Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users","volume":"21","author":"Vergara","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1756283X12437358","article-title":"Overutilization of proton-pump inhibitors: What the clinician needs to know","volume":"5","author":"Heidelbaugh","year":"2012","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_6","first-page":"52","article-title":"Evaluation of Omeprazole, Lansoprazole, Pantoprazole, and Rabeprazole in the Treatment of Acid-Related Diseases","volume":"40","author":"Welage","year":"2000","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_7","unstructured":"(2019, April 30). Internal Clinical Guidelines Team (UK) Gastro-Oesophageal Reflux Disease and Dyspepsia in Adults: Investigation and Management. Available online: https:\/\/www.nice.org.uk\/guidance\/cg184\/resources\/gastrooesophageal-reflux-disease-and-dyspepsia-in-adults-investigation-and-management-pdf-35109812699845."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_9","first-page":"728","article-title":"Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/pds.1972","article-title":"Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice","volume":"19","author":"McGowan","year":"2010","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_11","unstructured":"(2014, July 15). Tables of Prescription Volumes and Government Costs (Expenditures) under the Pharmaceutical Benefits Scheme (PBS), Available online: http:\/\/www.pbs.gov.au\/info\/statistics\/expenditure-and-prescriptions-30- 06-2014."},{"key":"ref_12","unstructured":"Burlington, M. (2013). Declining Medicine Use and Costs: For Better or Worse? A Review of the Use of Medicines in the United States in 2012, IMS Institute for Healthcare Informatics."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejim.2016.10.007","article-title":"The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal","volume":"37","author":"Savarino","year":"2017","journal-title":"Eur. J. Int. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00774-015-0699-6","article-title":"Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors","volume":"34","author":"Bahtiri","year":"2016","journal-title":"J. Bone Min. Metab."},{"key":"ref_15","first-page":"193","article-title":"Effect of long-term proton pump inhibitors on bone mineral density","volume":"96","author":"Romdhane","year":"2018","journal-title":"Tunis Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/1756-185X.12866","article-title":"Proton pump inhibitors use and change in bone mineral density","volume":"19","author":"Arj","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1097\/00007632-199712151-00003","article-title":"Frederick Kaplan Osteoporosis: Definition and Clinical Presentation","volume":"22","author":"Glaser","year":"1997","journal-title":"Spine (Phila. Pa. 1976)."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/archinte.162.19.2217","article-title":"Undertreatment of osteoporosis in men with hip fracture","volume":"162","author":"Kiebzak","year":"2002","journal-title":"Arch. Int. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/gerona\/63.8.867","article-title":"The association of race, gender, and comorbidity with mortality and function after hip fracture","volume":"63","author":"Penrod","year":"2008","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/bmj.307.6914.1248","article-title":"Mortality and morbidity after hip fractures","volume":"307","author":"Keene","year":"1993","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00198-002-1316-9","article-title":"Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: A 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study","volume":"14","author":"Hasserius","year":"2003","journal-title":"Osteoporos. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF01623184","article-title":"Hip fractures in the elderly: A world-wide projection","volume":"2","author":"Cooper","year":"1992","journal-title":"Osteoporos. Int."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Panula, J., Pihlajam\u00e4ki, H., Mattila, V.M., Jaatinen, P., Vahlberg, T., Aarnio, P., and Kivel\u00e4, S.L. (2011). Mortality and cause of death in hip fracture patients aged 65 or older\u2014A population-based study. BMC Musculoskelet. Disord., 12.","DOI":"10.1186\/1471-2474-12-105"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1007\/s11999-014-3820-6","article-title":"Surgery for Hip Fracture Yields Societal Benefits That Exceed the Direct Medical Costs","volume":"472","author":"Gu","year":"2014","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.00015.2012","article-title":"Gastric Acid, Calcium Absorption, and Their Impact on Bone Health","volume":"93","author":"Kopic","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12020-015-0576-z","article-title":"The relationship between long-term proton pump inhibitor therapy and skeletal frailty","volume":"49","author":"Lau","year":"2015","journal-title":"Endocrine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11938-014-0030-y","article-title":"Proton Pump Inhibitors and Risk of Bone Fractures","volume":"12","author":"Leontiadis","year":"2014","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00198-015-3403-8","article-title":"Calcium, proton pump inhibitors, and fracture risk","volume":"27","author":"Sugiyama","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s41999-017-0022-2","article-title":"Proton pump inhibitors therapy and the risk of hip fracture in older people in Taiwan","volume":"9","author":"Lai","year":"2018","journal-title":"Eur. Geriatr. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.bone.2012.09.028","article-title":"Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region","volume":"52","author":"Reyes","year":"2013","journal-title":"Bone"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.annepidem.2014.01.004","article-title":"Proton-pump inhibitor use and hip fractures in men: A population-based case-control study","volume":"24","author":"Adams","year":"2014","journal-title":"Ann. Epidemiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00198-016-3510-1","article-title":"Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: A nationwide population-based analysis","volume":"27","author":"Chen","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00198-012-2112-9","article-title":"The effect of proton pump inhibitors on fracture risk: Report from the Canadian Multicenter Osteoporosis Study","volume":"24","author":"Fraser","year":"2013","journal-title":"Osteoporos. Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/phar.1410","article-title":"Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting","volume":"34","author":"Johansson","year":"2014","journal-title":"Pharmacotherapy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.bone.2015.08.024","article-title":"The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study","volume":"81","author":"Tett","year":"2015","journal-title":"Bone"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/pds.4406","article-title":"Proton pump inhibitor use and the risk of fractures among an older adult cohort","volume":"27","author":"Harding","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1038\/s41598-017-05552-1","article-title":"Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00223-014-9855-6","article-title":"The relationship between proton pump inhibitor adherence and fracture risk in the elderly","volume":"94","author":"Ding","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.maturitas.2014.05.019","article-title":"Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women the WHILA study","volume":"78","author":"Moberg","year":"2014","journal-title":"Maturitas"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s00198-015-3168-0","article-title":"Use of proton pump inhibitors is associated with fractures in young adults: A population-based study","volume":"26","author":"Freedberg","year":"2015","journal-title":"Osteoporos. Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/jbmr.2279","article-title":"Long-term proton pump inhibitor therapy and falls and fractures in elderly women: A prospective cohort study","volume":"29","author":"Lewis","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s00535-012-0722-9","article-title":"A population-based case-control study: Proton pump inhibition and risk of hip fracture by use of bisphosphonate","volume":"48","author":"Lee","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/apt.14589","article-title":"Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer\u2019s disease\u2014A nested case-control study","volume":"47","author":"Tolppanen","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.2215\/CJN.02190218","article-title":"Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis","volume":"13","author":"Vangala","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1053\/j.ajkd.2016.09.019","article-title":"Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients","volume":"69","author":"Lenihan","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00198-017-4262-2","article-title":"Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: A population-based cohort study","volume":"29","author":"Lin","year":"2018","journal-title":"Osteoporos. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1046\/j.1365-2036.1999.00545.x","article-title":"The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers","volume":"13","author":"Dammann","year":"1999","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1172\/JCI107952","article-title":"pH dependence of acid secretion and gastrin release in normal and ulcer subjects","volume":"55","author":"Walsh","year":"1975","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0016-5085(90)91226-V","article-title":"Gastrin Secretion From Human Antral G Cells in Culture","volume":"99","author":"Campos","year":"1990","journal-title":"Gastroenterology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/gut.10.5.379","article-title":"Studies on the G cells of the pyloric mucosa, the probable site of gastrin secretion","volume":"10","author":"Solcia","year":"1969","journal-title":"Gut"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1152\/physrev.1995.75.1.155","article-title":"Gastric acid secretion","volume":"75","author":"Hersey","year":"1995","journal-title":"Physiol. Rev."},{"key":"ref_53","first-page":"347","article-title":"Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa","volume":"89","year":"1997","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2036.1999.00466.x","article-title":"Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: A case-control study","volume":"13","author":"Sanduleanu","year":"1999","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-2999(00)00080-7","article-title":"Effect of rabeprazole on histamine synthesis in enterochromaffin-like cells of mast cell-deficient (Ws\/Ws) rats","volume":"394","author":"Nakamura","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00418-003-0583-7","article-title":"Immunoelectron microscopic study for histamine in the gastric enterochromaffin-like cells of rats treated with the proton pump inhibitor lansoprazole","volume":"120","author":"Tanabe","year":"2003","journal-title":"Histochem. Cell Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejphar.2003.09.011","article-title":"Direct effects of proton pump inhibitors on histamine release from rat enterochromaffin-like cells","volume":"481","author":"Yokota","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00042737-200505000-00013","article-title":"Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa","volume":"17","author":"Rindi","year":"2005","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_59","first-page":"117","article-title":"Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett\u2019s esophagus","volume":"30","author":"Nishi","year":"2005","journal-title":"Tokai J. Exp. Clin. Med."},{"key":"ref_60","first-page":"123","article-title":"Effects of Helicobacter pylori infection and long-term proton pump inhibitor use on enterochromaffin-like cells","volume":"25","author":"Bektas","year":"2012","journal-title":"Ann. Gastroenterol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Schayer, R.W. (1966). Enzymatic formation of histamine from histidine. Histamine and Anti-histaminics, Springer.","DOI":"10.1007\/978-3-662-12016-3_27"},{"key":"ref_62","first-page":"109","article-title":"Biogenesis of histamine","volume":"18","author":"Schayer","year":"1952","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2353\/ajpath.2009.080871","article-title":"Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts","volume":"174","author":"Baroukh","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/00365529409092460","article-title":"Growth of the parathyroid glands in omeprazole-treated chickens","volume":"29","author":"Hakanson","year":"1994","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s002239900325","article-title":"Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake","volume":"61","author":"Samuelsson","year":"1997","journal-title":"Calcif. Tissue Int."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01352010","article-title":"Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans","volume":"53","author":"Mizunashi","year":"1993","journal-title":"Calcif. Tissue Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3109\/00365527709181713","article-title":"The parathyroid glands in experimentally induced hypergastrinemia in the rat","volume":"12","author":"Grimelius","year":"1977","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11894-012-0290-4","article-title":"Chronic proton pump inihibitor therapy and calcium metabolism","volume":"14","author":"Yang","year":"2012","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/jgs.13661","article-title":"Hyperparathyroidism Associated with Long-Term Proton Pump Inhibitors Independent of Concurrent Bisphosphonate Therapy in Elderly Adults","volume":"63","author":"Hinson","year":"2015","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/03009738209178426","article-title":"Evaluation of Parathyroid Function in Patients with Hypergastrinaemia and Pernicious Anaemia","volume":"87","author":"Selking","year":"1982","journal-title":"Upsala J. Med. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"G649","DOI":"10.1152\/ajpgi.00366.2016","article-title":"Gastrin induces parathyroid hormone-like hormone expression in gastric parietal cells","volume":"312","author":"Keeley","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00041552-199707000-00002","article-title":"Parathyroid hormone-related peptide and the parathyroid hormone\/parathyroid hormone-related peptide receptor in skeletal development","volume":"6","author":"Karaplis","year":"1997","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_73","first-page":"415","article-title":"The biological action of parathyroid hormone-related peptide (PTHrP) and fibroblast growth factor receptor 3 (FGFR3) on bone and cartilage","volume":"75","author":"Amizuka","year":"2000","journal-title":"Kaibogaku Zasshi"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00041552-200007000-00006","article-title":"Parathyroid hormone-related peptide and Indian hedgehog","volume":"9","author":"Chung","year":"2000","journal-title":"Curr. Opin. Nephrol. Hypertens"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0959-8049(97)10130-7","article-title":"Parathyroid hormone-related protein (PTHrP) and hypercalcaemia","volume":"34","author":"Grill","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"32s","DOI":"10.1016\/S0753-3322(00)80008-6","article-title":"Parathyroid hormone-related peptide and bone: Pathological and physiological aspects","volume":"54","author":"Inoue","year":"2000","journal-title":"Biomed. Pharmacother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s004670000343","article-title":"Role of parathyroid hormone-related peptide and Indian hedgehog in skeletal development","volume":"14","author":"Juppner","year":"2000","journal-title":"Pediatr. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1601-0825.1997.tb00046.x","article-title":"Parathyroid hormone-related protein (PTHrP) as a regulating factor of endochondral bone formation","volume":"3","author":"Suda","year":"1997","journal-title":"Oral. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1258\/0007142991902501","article-title":"Bone health: The role of micronutrients","volume":"55","author":"New","year":"1999","journal-title":"Br. Med. Bull."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1232S","DOI":"10.1093\/ajcn\/81.5.1232","article-title":"Osteoporosis: The role of micronutrients","volume":"81","author":"Nieves","year":"2005","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000486060","article-title":"Physiology of the Calcium-Parathyroid Hormone-Vitamin D Axis","volume":"50","author":"Goltzman","year":"2018","journal-title":"Front. Horm. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/bulm.1999.0146","article-title":"Parathyroid Hormone Temporal Effects on Bone Formation and Resorption","volume":"62","author":"Kroll","year":"2000","journal-title":"Bull. Math. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pop.2008.01.007","article-title":"Disorders Involving Calcium, Phosphorus, and Magnesium","volume":"35","author":"Moe","year":"2008","journal-title":"Prim. Care"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.amjmed.2005.02.007","article-title":"Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial","volume":"118","author":"Madden","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.3390\/nu5083022","article-title":"Magnesium and Osteoporosis: Current State of Knowledge and Future Research Directions","volume":"5","author":"Castiglioni","year":"2013","journal-title":"Nutrients"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bcp.12846","article-title":"Proton pump inhibitor associated hypomagnasaemia\u2014A cause for concern?","volume":"81","author":"Begley","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/0004563215569423","article-title":"The association between the use of proton pump inhibitors and the risk of hypomagnesemia: A systematic review and meta-analysis","volume":"52","author":"Cegla","year":"2015","journal-title":"Ann. Clin. Biochem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/jgh.14141","article-title":"Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use","volume":"33","author":"Chowdhry","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5152\/tjg.2016.0284","article-title":"Proton pump inhibitor use for 12 months is not associated with changes in serum magnesium levels: A prospective open label comparative study","volume":"28","author":"Bahtiri","year":"2017","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Hughes, J., Chiu, D.Y., Kalra, P.A., and Green, D. (2018). Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197400"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejim.2016.01.026","article-title":"Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis?","volume":"30","author":"Mikolasevic","year":"2016","journal-title":"Eur. J. Int. Med."},{"key":"ref_92","first-page":"21689","article-title":"Proton pump inhibitors use in hemodialysis patients and serum magnesium levels","volume":"8","author":"Erdem","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1139\/apnm-2016-0020","article-title":"Proton-pump inhibitor therapy and vitamin B12 status in an inpatient hospital setting","volume":"41","author":"Hartman","year":"2016","journal-title":"Appl. Physiol. Nutr. Metab"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jclinepi.2003.08.015","article-title":"A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults","volume":"57","author":"Valuck","year":"2004","journal-title":"J. Clin. Epidemiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1515\/CCLM.2007.362","article-title":"The role of hyperhomocysteinemia as well as folate, vitamin B6 and B12 deficiencies in osteoporosis\u2014A systematic review","volume":"45","author":"Herrmann","year":"2007","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa011613","article-title":"Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer\u2019s Disease","volume":"346","author":"Seshadri","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archneur.55.11.1449","article-title":"Folate, Vitamin B12, and Serum Total Homocysteine Levels in Confirmed Alzheimer Disease","volume":"55","author":"Clarke","year":"1998","journal-title":"Arch. Neurol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1100\/2012\/872173","article-title":"Alzheimer\u2019s Disease and Risk of Hip Fracture: A Meta-Analysis Study","volume":"2012","author":"Zhao","year":"2012","journal-title":"Sci. World J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"211","DOI":"10.7326\/0003-4819-120-3-199402010-00006","article-title":"Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12)","volume":"120","author":"Marcuard","year":"1994","journal-title":"Ann. Int. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/imj.12697","article-title":"Association between vitamin B12 deficiency and long-term use of acid-lowering agents: A systematic review and meta-analysis","volume":"45","author":"Jung","year":"2015","journal-title":"Int. Med. J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.3390\/nu7053322","article-title":"B-Vitamins and Bone Health\u2013A Review of the Current Evidence","volume":"7","author":"Dai","year":"2015","journal-title":"Nutrients"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-012-2233-1","article-title":"Dietary B vitamin intake and risk of hip fracture: The Singapore Chinese Health Study","volume":"24","author":"Dai","year":"2013","journal-title":"Osteoporos. Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/qjmed\/hcy245","article-title":"Risk of Fall in Patients Taking Proton Pump Inhibitors: A Meta-Analysis","volume":"112","author":"Lapumnuaypol","year":"2018","journal-title":"QJM"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.3390\/nu7042176","article-title":"B vitamins, Homocysteine and bone health","volume":"7","author":"Fratoni","year":"2015","journal-title":"Nutrients"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Kennedy, D. (2016). B Vitamins and the Brain: Mechanisms, Dose and Efficacy\u2014A Review. Nutrients, 8.","DOI":"10.3390\/nu8020068"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40279-013-0041-1","article-title":"The Importance of Trunk Muscle Strength for Balance, Functional Performance, and Fall Prevention in Seniors: A Systematic Review","volume":"43","author":"Granacher","year":"2013","journal-title":"Sport. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2005.03.009","article-title":"Muscle strength is a determinant of bone mineral content in the hemiparetic upper extremity: Implications for stroke rehabilitation","volume":"37","author":"Pang","year":"2005","journal-title":"Bone"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.gerinurse.2007.10.016","article-title":"Simple Balance and Mobility Tests Can Assess Falls Risk When Cognition Is Impaired","volume":"29","author":"McMichael","year":"2008","journal-title":"Geriatr. Nurs. (Minneap)."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.3390\/nu5114462","article-title":"Vitamin B12 Deficiency in Relation to Functional Disabilities","volume":"5","author":"Oberlin","year":"2013","journal-title":"Nutrients"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1196\/annals.1365.035","article-title":"Bone remodeling","volume":"1092","author":"Hadjidakis","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_111","first-page":"877","article-title":"Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts","volume":"26","author":"Hyun","year":"2010","journal-title":"Int. J. Mol. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1111\/febs.12478","article-title":"Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity","volume":"280","author":"Reis","year":"2013","journal-title":"FEBS J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"413097","DOI":"10.1155\/2015\/413097","article-title":"Pantoprazole Decreases Cell Viability and Function of Human Osteoclasts In Vitro","volume":"2015","author":"Prause","year":"2015","journal-title":"Mediat. Inflamm"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.injury.2014.05.005","article-title":"Pantoprazole increases cell viability and function of primary human osteoblasts in vitro","volume":"45","author":"Prause","year":"2014","journal-title":"Injury"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/9\/1571\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:49:16Z","timestamp":1760186956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/9\/1571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,5]]},"references-count":114,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["ijerph16091571"],"URL":"https:\/\/doi.org\/10.3390\/ijerph16091571","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,5]]}}}